Kung Winston 4

What Happened

• Winston Kung, a director of Janux Therapeutics (NASDAQ: JANX), received equity awards on June 11, 2026: 5,500 restricted stock units (RSUs) and a derivative award covering 15,500 shares (options/option-like award). Both awards were reported as acquired at $0.00 on the Form 4 filed 2026-06-12. Total awards equal 21,000 shares on grant.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 12, 2026 (within the two-business-day reporting window).
• Price: Reported acquisition price $0.00 (typical for grant awards).
• Vesting/terms:
  • RSUs (5,500): Each RSU converts to one share upon vesting. Vesting occurs on the earlier of (i) June 11, 2027 or (ii) the next annual stockholders’ meeting, subject to continuous service. (Footnote F1)
  • Derivative award/options (15,500): Vest in equal monthly installments over the 12 months following June 11, 2026, but will be fully vested on the date of the next annual meeting if earlier, subject to continuous service. (Footnote F2)
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication of a sale, tax withholding, 10b5-1 plan, or late filing in the disclosed Form 4.

Context

• RSUs are a contingent right to receive company stock upon vesting and do not represent immediately tradable shares until vested and delivered.
• The derivative award appears to be an option or option-like grant with time-based vesting; there is no indication these shares were exercised or sold.
• Grants to directors are common compensation practices and are not in themselves a buy/sell signal.